Patents by Inventor Jeffrey H. Baxter
Jeffrey H. Baxter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8785495Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: GrantFiled: January 11, 2012Date of Patent: July 22, 2014Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Patent number: 8785496Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: GrantFiled: January 11, 2012Date of Patent: July 22, 2014Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Patent number: 8778993Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: GrantFiled: January 11, 2012Date of Patent: July 15, 2014Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Patent number: 8778994Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.Type: GrantFiled: January 11, 2012Date of Patent: July 15, 2014Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
-
Patent number: 8609725Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: GrantFiled: January 11, 2012Date of Patent: December 17, 2013Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
-
Publication number: 20130011498Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: January 10, 2013Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
-
Publication number: 20120196829Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: August 2, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Publication number: 20120189715Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Publication number: 20120189714Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Publication number: 20120189717Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
-
Publication number: 20120189716Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Publication number: 20120177752Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 12, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Patent number: 8217077Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: GrantFiled: December 29, 2004Date of Patent: July 10, 2012Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Pradip Mukerji, Anne C. Voss, Michael J. Tisdale
-
Publication number: 20090005544Abstract: Disclosed is a process comprising: mixing a soy protein-containing material with an aqueous medium; removing the non-solubilized solids from the slurry to form an alkaline liquid containing solubilized soy protein; adjusting the pH of the solubilized soy protein liquid to between about 3.8 and about 6.6, to precipitate soy protein from the liquid; separating the precipitated soy protein from the pH-adjusted soy protein liquid; resolubilizing the separated soy protein precipitate in an aqueous medium at a pH of from about 1.8 to 3.2; treating the resolubilized soy protein with at least one water-soluble calcium salt to form a calcium-enriched soy protein mixture; precipitating soy protein from the calcium-enriched soy protein mixture by adjusting the pH of the mixture to between about 3.8 and about 6.6; separating the precipitated soy protein from the calcium-enriched soy protein mixture; and washing to form calcium-enriched soy protein isolate having selectively reduced manganese concentrations.Type: ApplicationFiled: June 25, 2008Publication date: January 1, 2009Inventors: Louis I. Ndife, Chad R. Cole, Jeffrey H. Baxter
-
Publication number: 20040081708Abstract: Methods and compositions for providing glutamine supplementation to a human by orally administering an effective amount of N-acetyl-L-glutamine or a nutritionally acceptable salt thereof. The N-acetyl L-glutamine or a nutritionally acceptable salt thereof can be incorporated into any liquid composition that is suitable for human consumption. Examples of suitable compositions include aqueous solutions such as for use as oral rehydration solutions and liquid nutritional formulas (including enteral formulas, oral formulas, formulas for adults, formulas for children and formulas for infants). The quantity of N-acetyl-L-glutamine or nutritionally acceptable salt thereof can vary widely but typically, these compositions will contain sufficient N-acetyl-L-glutamine or a nutritionally acceptable salt thereof to provide at least 140 mg of total glutamine per kg of body weight per day.Type: ApplicationFiled: July 18, 2003Publication date: April 29, 2004Inventor: Jeffrey H. Baxter
-
Publication number: 20030134851Abstract: Methods and compositions for providing glutamine supplementation to a human by orally administering an effective amount of N-acetyl-L-glutamine or a nutritionally acceptable salt thereof. The N-acetyl L-glutamine or a nutritionally acceptable salt thereof can be incorporated into any liquid composition that is suitable for human consumption. Examples of suitable compositions include aqueous solutions such as for use as oral rehydration solutions and liquid nutritional formulas (including enteral formulas, oral formulas, formulas for adults, formulas for children and formulas for infants). The quantity of N-acetyl-L-glutamine or nutritionally acceptable salt thereof can vary widely but typically, these compositions will contain sufficient N-acetyl-L-glutamine or a nutritionally acceptable salt thereof to provide at least 140 mg of total glutamine per kg of body weight per day.Type: ApplicationFiled: October 8, 2002Publication date: July 17, 2003Inventors: Jeffrey H. Baxter, Jose Maria Lopez Pedrosa, Ricardo Rueda Cabrera
-
Publication number: 20030129262Abstract: The present invention is directed to methods and compositions regarding induction of apoptosis in a cell and treatment of cancer in an individual wherein methionine deprivation of the cell is followed by methionine repletion of the cell. The methionine deprivation of the cell results in G2 arrest in the cell, leading to DNA damage in the cell. Upon readministration of methionine to the cell, the damaged cell exits G2 arrest and enters into apoptosis. In a specific embodiment, a therapeutic effect is elicited by cycling the patient between a methionine-depleted diet and a normal, methionine-replete diet. The present invention also regards chronic methionine deprivation for treatment of cancer in a human, in addition to methods for methionine restriction as adjunctive therapy for other cancer treatment methods.Type: ApplicationFiled: August 30, 2002Publication date: July 10, 2003Inventors: Daniel E. Epner, Jeffrey H. Baxter, Jeffrey T. Kivi, Robert G. Hards
-
Publication number: 20030099722Abstract: Methods and compositions for providing glutamine supplementation to a human by orally administering an effective amount of N-acetyl-L-glutamine or a nutritionally acceptable salt thereof. The N-acetyl L-glutamine or a nutritionally acceptable salt thereof can be incorporated into any liquid composition that is suitable for human consumption. Examples of suitable compositions include aqueous solutions such as for use as oral rehydration solutions and liquid nutritional formulas (including enteral formulas, oral formulas, formulas for adults, formulas for children and formulas for infants). The quantity of N-acetyl-L-glutamine or nutritionally acceptable salt thereof can vary widely but typically, these compositions will contain sufficient N-acetyl-L-glutamine or a nutritionally acceptable salt thereof to provide at least 140 mg of total glutamine per kg of body weight per day.Type: ApplicationFiled: October 9, 2001Publication date: May 29, 2003Inventor: Jeffrey H. Baxter
-
Patent number: 5700590Abstract: An improved enteral formula containing ribo-nucleotide equivalents (RNA, mono-, di- and triphosphate nucleotides, nucleosides and adducts such as activated sugars) at a level of at least 10 mg/100 Kcal (kilocalorie) of formula. More specifically, an infant formula containing at least 10 milligrams of nucleotide equivalents per 100 Kcal of formula where the nucleotide equivalents consist of RNA; mono-, di-, and triphosphate esters of adenosine, cytidine, guanosine, and uridine, and the d-ribose adducts thereof; and wherein the weight ratio of said cytidine nucleotide equivalents to said uridine nucleotide equivalents is 1.5:1 to 2.6:1; of said cytidine nucleotide equivalent to said adenosine nucleotide equivalents is 2:1 to 3.9:1; and of said cytidine nucleotide equivalents to said guanosine nucleotide equivalents is 1.75:1 to 2.8:1, is disclosed. The formula comprises carbohydrates, lipids, proteins, vitamins and minerals and four (4) ribo-nucleotide equivalents at specific levels and ratios.Type: GrantFiled: January 11, 1996Date of Patent: December 23, 1997Assignee: Abbott LaboratoriesInventors: Marc Leif Masor, James Lee Leach, Bruce Edward Molitor, John Durand Benson, Jeffrey H. Baxter
-
Patent number: 5576300Abstract: A method of preventing or treating infection by human rotavirus by administering an enteral nutritional product containing either bovine .kappa.-casein or human .kappa.-casein at a concentration greater than that found in human or bovine milk and sufficient to inhibit infection of mammalian cells by human rotavirus.Type: GrantFiled: September 16, 1994Date of Patent: November 19, 1996Assignee: Abbott LaboratoriesInventors: Pradip Mukerji, Pedro A. Prieto, Amanda E.-Y. Seo, Jeffrey H. Baxter, Richard D. Cummings